MarketMoodz
Moderna Posts 5-Year Melanoma Results; CEPI Ebola Deal, Stock Dips
Moderna reported five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial showing intismeran autogene (mRNA-4157/V940) plus Merck’s KEYTRUDA cut recurrence-free survival risk by 49% and distant-metastasis-free survival risk by 59% versus KEYTRUDA alone after a median 60.3 months. The company also expanded its partnership with CEPI to develop a Bundibugyro ebolavirus (BDBV) mRNA vaccine with up to $50 million in CEPI support, while Moderna shares slipped roughly 2.8% to about $45.88 at publication.
Key Takeaways
- Phase 2b KEYNOTE-942 five-year follow-up (median 60.3 months) reports 49% reduction in recurrence-free survival (RFS) risk with mRNA-4157/V940 plus pembrolizumab versus pembrolizumab alone.
- Distant metastasis–free survival (DMFS) risk fell by 59% versus pembrolizumab alone in the same analysis.
- Results align with earlier ASCO-era readouts (≈34.9 months) that showed similar durable benefit (49% RFS, 62% DMFS reductions).
- Moderna expanded CEPI collaboration to develop a Bundibugyro ebolavirus (BDBV) mRNA vaccine, with CEPI committing up to $50 million for preclinical and Phase 1 work and parallel manufacturing planning.
- MRNA shares were down about 2.8% to ~$45.88 at publication, reflecting investor caution despite positive clinical and public-health news.
People Involved
- No specific individuals mentioned
Entities Involved
- Moderna, Inc. (MRNA)Developer of mRNA-4157/V940 personalized neoantigen vaccine and company releasing the trial and partnership updates
- Merck & Co., Inc. (MRK)Manufacturer of KEYTRUDA (pembrolizumab) and partner in KEYNOTE-942 trial
- Coalition for Epidemic Preparedness Innovations (CEPI)Public-health funder expanding collaboration with Moderna and committing up to $50 million for BDBV vaccine development
- KEYNOTE-942/mRNA-4157-P201Phase 2b clinical trial evaluating individualized neoantigen vaccine mRNA-4157/V940 plus pembrolizumab in high-risk stage III/IV melanoma after resection
- mRNA-4157/V940 (intismeran autogene)Personalized neoantigen mRNA cancer vaccine candidate evaluated in combination with pembrolizumab
MarketMoodz Analysis
For investors, five-year durability matters. A 49% reduction in recurrence and a 59% reduction in distant metastasis at a median 60.3 months would signal sustained benefit for an individualized neoantigen approach when paired with checkpoint inhibition — a profile that could strengthen regulatory conversations and commercial value if replicated in larger trials. The readout reinforces earlier ASCO-era signals (≈34.9 months) and supports the thesis that personalized mRNA cancer vaccines can produce durable immune responses when combined with established immunotherapies.
The CEPI expansion complements the clinical news by de-risking infectious-disease work and broadening Moderna’s funding mix. Up to $50 million of CEPI support for preclinical, Phase 1 testing and parallel manufacturing planning shortens the pathway to larger trials and reduces cash burn on early-stage development — a financing lever investors prize in capital-intensive biotech. Near-term investor focus should be on primary-source confirmation of the five-year metrics, clarity on regulatory next steps or planned registrational trials, and updates on the BDBV program’s milestones and manufacturing timelines; each could act as a catalyst or a re-rating trigger for MRNA shares.
Source: Original Article